Bile Acids, FXR, and Metabolic Effects of Bariatric Surgery

Journal of Obesity

Volumn 2016, Issue , 2016, Pages

  Noel, Olivier F ^a,b   Still, Christopher D ^c   Argyropoulos, George ^c   Edwards, Michael ^a   Gerhard, Glenn S ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; FARNESOID X RECEPTOR; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

BARIATRIC SURGERY; COMPLEMENT ALTERNATIVE PATHWAY; ENERGY METABOLISM; GENE; GENE CONTROL; HUMAN; LIPID METABOLISM; METABOLISM; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION; COMPLICATION; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; IMMUNOLOGY; INSULIN RESISTANCE; OBESITY, MORBID; TREATMENT OUTCOME;

BARIATRIC SURGERY; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; OBESITY, MORBID; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84960977657     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2016/4390254     Document Type: Review

References (82)

1. R. Sturm and A. Hattori, "Morbid obesity rates continue to rise rapidly in the United States, " International Journal of Obesity, vol. 37, no. 6, pp. 889-891, 2013.
2. D. Hofsø, T. Jenssen, H. Hager, J. Røislien, and J. Hjelmesæth, "Fasting plasma glucose in the screening for type 2 diabetes in morbidly obese subjects, " Obesity Surgery, vol. 20, no. 3, pp. 302-307, 2010.
3. J. Chmelar, K.-J. Chung, and T. Chavakis, "The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance, "Thrombosis and Haemostasis, vol. 109, no. 3, pp. 399-406, 2013.
4. A. W. Ferrante Jr., "Obesity-induced inflammation: a metabolic dialogue in the language of inflammation, " Journal of Internal Medicine, vol. 262, no. 4, pp. 408-414, 2007.
5. S. Schenk, M. Saberi, and J. M. Olefsky, "Insulin sensitivity: modulation by nutrients and inflammation, " The Journal of Clinical Investigation, vol. 118, no. 9, pp. 2992-3002, 2008.
6. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., "Obesity is associated with macrophage accumulation in adipose tissue, " The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796-1808, 2003.
7. C. N. Lumeng, S. M. Deyoung, and A. R. Saltiel, "Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins, " American Journal of Physiology-Endocrinology and Metabolism, vol. 292, no. 1, pp. E166-E174, 2007.
8. H. Xu, G. T. Barnes, Q. Yang et al., "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, "The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821-1830, 2003.
9. J. Westerink and F. L. J. Visseren, "Pharmacological and nonpharmacological interventions to influence adipose tissue function, " Cardiovascular Diabetology, vol. 10, article 13, 2011.
10. K. L. Butner, S. M. Nickols-Richardson, S. F. Clark, W. K. Ramp, and W. G. Herbert, "A review of weight loss following Rouxen-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin, " Obesity Surgery, vol. 20, no. 5, pp. 559-568, 2010.
11. H. Buchwald, R. Estok, K. Fahrbach et al., "Weight and type 2 diabetes after bariatric surgery: systematic review and metaanalysis, " The American Journal of Medicine, vol. 122, no. 3, pp. 248. e5-256. e5, 2009.
12. J. B. Dixon, D. K. Murphy, J. E. Segel, and E. A. Finkelstein, "Impact of laparoscopic adjustable gastric banding on type 2 diabetes, " Obesity Reviews, vol. 13, no. 1, pp. 57-67, 2012.
13. C. V. Ferchak and L. F. Meneghini, "Obesity, bariatric surgery and type 2 diabetes-a systematic review, " Diabetes/Metabolism Research and Reviews, vol. 20, no. 6, pp. 438-445, 2004.
14. H. M. Heneghan, S. Nissen, and P. R. Schauer, "Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia, " Current Atherosclerosis Reports, vol. 14, no. 6, pp. 579-587, 2012.
15. J. P. Thaler and D. E. Cummings, "Minireview: hormonal and metabolicmechanisms of diabetes remission after gastrointestinal surgery, " Endocrinology, vol. 150, no. 6, pp. 2518-2525, 2009.
16. A. D. Miras and C. W. le Roux, "Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery" International Journal of Obesity, vol. 38, no. 3, pp. 325-333, 2014.
17. G. Mingrone, S. Panunzi, A. De Gaetano et al., "Bariatric surgery versus conventional medical therapy for type 2 diabetes, " The New England Journal of Medicine, vol. 366, no. 17, pp. 1577-1585, 2012.
18. R. E. Allen, T. D. Hughes, J. L. Ng et al., "Mechanisms behind the immediate effects of Roux-en-Y gastric bypass surgery on type 2 diabetes, " Theoretical Biology and MedicalModelling, vol. 10, no. 1, article 45, 2013.
19. H. Ashrafian, M. Bueter, K. Ahmed et al., "Metabolic surgery: an evolution through bariatric animal models, " Obesity Reviews, vol. 11, no. 12, pp. 907-920, 2010.
20. K. T. Nguyen and J. Korner, "The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgery, " Current Diabetes Reports, vol. 14, article 481, 2014.
21. S. Madsbad, C. Dirksen, and J. J. Holst, "Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery, " TheLancetDiabetes and Endocrinology, vol. 2, no. 2, pp. 152-164, 2014.
22. F. A. McAlister, J. Man, L. Bistritz, H. Amad, and P. Tandon, "Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes, " Diabetes Care, vol. 26, no. 5, pp. 1518-1524, 2003.
23. G. Fruhbeck and R. Nogueiras, "GLP-1: the oracle for gastric bypass" Diabetes, vol. 63, no. 2, pp. 399-401, 2014.
24. J. Schirra and B. Göke, "GLP-1-a candidate humoral mediator for glucose control after Roux-en-Y gastric bypass, " Diabetes, vol. 63, no. 2, pp. 387-389, 2014.
25. M. Mokadem, J. F. Zechner, R. F. Margolskee, D. J. Drucker, and V. Aguirre, "Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency, " Molecular Metabolism, vol. 3, no. 2, pp. 191-201, 2014.
26. J. Ye, Z. Hao, M. B. Mumphrey et al., "GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents, " TheAmerican Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 306, no. 5, pp. R352-R362, 2014.
27. B. J. Sandler, R. Rumbaut, C. P. Swain et al., "Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve, " Surgical Endoscopy, vol. 25, no. 9, pp. 3028-3033, 2011.
28. K. K. Ryan, V. Tremaroli, C. Clemmensen et al., "FXR is a molecular target for the effects of vertical sleeve gastrectomy, " Nature, vol. 509, no. 7499, pp. 183-188, 2014.
29. P. O. Ganrot, K. Gydell, and H. Ekelund, "Serum concentration of alpha-2-macroglobulin, haptoglobin and alpha-1-antitrypsin in diabetes mellitus, " Acta Endocrinologica, vol. 55, no. 3, pp. 537-544, 1967.
30. F. G. Schaap, M. Trauner, and P. L. M. Jansen, "Bile acid receptors as targets for drug development, " Nature Reviews Gastroenterology and Hepatology, vol. 11, no. 1, pp. 55-67, 2014.
31. R. Kohli, D. Bradley, K. D. Setchell, J. C. Eagon, N. Abumrad, and S. Klein, "Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids, " Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp. E708-E712, 2013.
32. G. S. Gerhard, A. M. Styer, G. C. Wood et al., "A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass, " Diabetes Care, vol. 36, no. 7, pp. 1859-1864, 2013.
33. A. Myronovych, M. Kirby, K. K. Ryan et al., "Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner, " Obesity, vol. 22, no. 2, pp. 390-400, 2014.
34. M.-E. Patti, S. M. Houten, A. C. Bianco et al., "Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism, " Obesity, vol. 17, no. 9, pp. 1671-1677, 2009.
35. P. L. M. Jansen, J. van Werven, E. Aarts et al., "Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery, " Digestive Diseases, vol. 29, no. 1, pp. 48-51, 2011.
36. S. M. Houten, M. Watanabe, and J. Auwerx, "Endocrine functions of bile acids, " The EMBO Journal, vol. 25, no. 7, pp. 1419-1425, 2006.
37. J. Prawitt, S. Caron, and B. Staels, "Bile acidmetabolism and the pathogenesis of type 2 diabetes, " Current Diabetes Reports, vol. 11, no. 3, pp. 160-166, 2011.
38. M. O. Hoeke, J. Heegsma, M. Hoekstra, H. Moshage, and K. N. Faber, "Human FXR regulates SHP expression through direct binding to an LRH-1 binding site, independent of an IR-1 and LRH-1, " PLoS ONE, vol. 9, no. 2, Article ID e88011, 2014.
39. F. Kuipers, V. W. Bloks, and A. K. Groen, "Beyond intestinal soap-bile acids in metabolic control, " Nature Reviews Endocrinology, vol. 10, no. 8, pp. 488-498, 2014.
40. A. Fisette, P. Poursharifi, K. Oikonomopoulou, M. N. Munkonda, M. Lapointe, and K. Cianflone, "Paradoxical glucose-sensitizing yet proinflammatory effects of acute ASP administration in mice, " Mediators of Inflammation, vol. 2013, Article ID 713284, 9 pages, 2013.
41. R. Germinario, A. D. Sniderman, S. Manuel, S. P. Lefebvre, A. Baldo, and K. Cianflone, "Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein, " Metabolism, vol. 42, no. 5, pp. 574-580, 1993.
42. B. Cariou, K. van Harmelen, D. Duran-Sandoval et al., "The farnesoidXreceptormodulates adiposity and peripheral insulin sensitivity inmice, " The Journal of Biological Chemistry, vol. 281, no. 16, pp. 11039-11049, 2006.
43. E. Hertle, M. M. J. van Greevenbroek, and C. D. A. Stehouwer, "Complement C3: an emerging risk factor in cardiometabolic disease, " Diabetologia, vol. 55, no. 4, pp. 881-884, 2012.
44. G. S. Hotamisligil, "Inflammation and metabolic disorders, " Nature, vol. 444, no. 7121, pp. 860-867, 2006.
45. O. A. Hamad, J. Bäck, P. H. Nilsson, B. Nilsson, and K. N. Ekdahl, "Platelets, complement, and contact activation: partners in inflammation and thrombosis, " Advances in Experimental Medicine and Biology, vol. 946, pp. 185-205, 2012.
46. D. Ricklin, G. Hajishengallis, K. Yang, and J. D. Lambris, "Complement: a key system for immune surveillance and homeostasis, " Nature Immunology, vol. 11, no. 9, pp. 785-797, 2010.
47. J. G. P. Sissons, R. J. West, J. Fallows et al., "The complement abnormalities of lipodystrophy, " The New England Journal of Medicine, vol. 294, no. 9, pp. 461-465, 1976.
48. M. Pattrick, J. Luckett, L. Yue, and C. Stover, "Dual role of complement in adipose tissue, " Molecular Immunology, vol. 46, no. 5, pp. 755-760, 2009.
49. A. Hernández-Mijares, C. Bañuls, L. Bellod et al., "Effect of weight loss on C3 and C4 components of complement in obese patients, " European Journal of Clinical Investigation, vol. 42, no. 5, pp. 503-509, 2012.
50. A. Onat, G. Can, R. Rezvani, and K. Cianflone, "Complement C3 and cleavage products in cardiometabolic risk, " Clinica Chimica Acta, vol. 412, no. 13-14, pp. 1171-1179, 2011.
51. T. Fujita, "Extra-immunological role of complement activation in diabetic nephropathy, " OA Nephrology, vol. 1, no. 2, article 19, 2013.
52. D. Kalant, S. A. Cain, M. Maslowska, A. D. Sniderman, K. Cianflone, and P. N. Monk, "The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein, " The Journal of Biological Chemistry, vol. 278, pp. 11123-11129, 2003.
53. M. Maslowska, A. D. Sniderman, R. Germinario, and K. Cianflone, "ASP stimulates glucose transport in cultured human adipocytes, " International Journal of Obesity, vol. 21, no. 4, pp. 261-266, 1997.
54. Y. Tao, K. Cianflone, A. D. Sniderman, S. P. Colby-Germinario, and R. J. Germinario, "Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line, " Biochimica et Biophysica Acta, vol. 1344, no. 3, pp. 221-229, 1997.
55. D. Gauvreau, A. Gupta, A. Fisette, F.-Q. Tom, and K. Cianflone, "Deficiency of C5L2 increases macrophage infiltration and alters adipose tissue function in mice, " PLoS ONE, vol. 8, no. 4, Article ID e60795, 2013.
56. A. Fisette, M. N. Munkonda, K. Oikonomopoulou, S. Paglialunga, J. D. Lambris, and K. Cianflone, "C5L2 receptor disruption enhances the development of diet-induced insulin resistance in mice, " Immunobiology, vol. 218, no. 1, pp. 127-133, 2013.
57. J. Li, P. C. Pircher, I. G. Schulman, and S. K. Westin, "Regulation of complement C3 expression by the bile acid receptor FXR, " The Journal of Biological Chemistry, vol. 280, no. 9, pp. 7427-7434, 2005.
58. K. Daily, V. R. Patel, P. Rigor, X. Xie, and P. Baldi, "MotifMap: integrative genome-wide maps of regulatory motif sites for model species, " BMC Bioinformatics, vol. 12, article 495, 2011.
59. G. Xie, Z. Peng, and J.-P. Raufman, "Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation, " The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 302, no. 9, pp. G1006-G1015, 2012.
60. S. S. Andrali, M. L. Smapley, N. L. Vanderford, and S. özcan, "Glucose regulation of insulin gene expression in pancreatic cells, " Biochemical Journal, vol. 415, no. 1, pp. 1-10, 2008.
61. Y. Xu, M. Ma, G. C. Ippolito, H. W. Schroeder Jr., M. C. Carroll, and J. E. Volanakis, "Complement activation in factor Ddeficient mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 25, pp. 14577-14582, 2001.
62. J. C. Lo, S. Ljubicic, B. Leibiger et al., "Adipsin is an adipokine that improves cell function in diabetes, " Cell, vol. 158, no. 1, pp. 41-53, 2014.
63. C. D. Still, G. C. Wood, X. Chuet al., "High allelicburdenof four obesity SNPs is associated with poorer weight loss outcomes following gastric bypass surgery, " Obesity, vol. 19, no. 8, pp. 1676-1683, 2011.
64. B. S. Moore, U. L. Mirshahi, E. A. Yost et al., "Long-termweightloss in gastric bypass patients carrying melanocortin 4 receptor variants, " PLoS ONE, vol. 9, no. 4, Article ID e93629, 2014.
65. U. L. Mirshahi, C. D. Still, K. K. Masker, G. S. Gerhard, D. J. Carey, and T. Mirshahi, "The MC4R(I251L) allele is associated with better metabolic status and more weight loss after gastric bypass surgery, " Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 12, pp. E2088-E2096, 2011.
66. E. S. Rinella, C. Still, Y. Shao et al., "Genome-wide association of single-nucleotide polymorphisms with weight loss outcomes after Roux-en-Y gastric bypass surgery, "The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 6, pp. E1131-E1136, 2013.
67. I. J. Hatoum, D. M. Greenawalt, C. Cotsapas, M. J. Daly, M. L. Reitman, and L. M. Kaplan, "Weight loss after gastric bypass is associated with a variant at 15q26. 1, " The American Journal of Human Genetics, vol. 92, no. 5, pp. 827-834, 2013.
68. A. E. Locke, B. Kahali, S. I. Berndt et al., "Genetic studies of body mass index yield new insights for obesity biology, " Nature, vol. 518, no. 7538, pp. 197-206, 2015.
69. D. Shungin, T. W. Winkler, D. C. Croteau-Chonka et al., "New genetic loci link adipose and insulin biology to body fat distribution, " Nature, vol. 518, no. 7538, pp. 187-196, 2015.
70. A. A. van der Klaauw and I. S. Farooqi, "The hunger genes: pathways to obesity, " Cell, vol. 161, no. 1, pp. 119-132, 2015.
71. X. Xie, P. Rigor, and P. Baldi, "MotifMap: a human genome-wide map of candidate regulatorymotif sites, " Bioinformatics, vol. 25, no. 2, pp. 167-174, 2009.
72. P. F. Duckworth, Z. Reno Vlahcevic, E. J. Studer et al., "Effect of hydrophobie bile acids on 3-hydroxy-3-methylglutarylcoenzyme A reductase activity andmRNA levels in the rat, " The Journal of Biological Chemistry, vol. 266, no. 15, pp. 9413-9418, 1991.
73. G. Vivacqua, A. Renzi, G. Carpino, A. Franchitto, and E. Gaudio, "Expression of brain derivated neurotrophic factor and of its receptors: TrKB and p75NT in normal and bile duct ligated rat liver, " Italian Journal of Anatomy and Embryology, vol. 119, no. 2, pp. 111-129, 2014.
74. M. Verlaet, A. Adamantidis, B. Coumans et al., "Human immune cells express ppMCH mRNA and functional MCHR1 receptor, " FEBS Letters, vol. 527, no. 1-3, pp. 205-210, 2002.
75. J. Krishnan, C. Danzer, T. Simka et al., "Dietary obesityassociated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system, " Genes & Development, vol. 26, pp. 259-270, 2012.
76. A. B. Crujeiras, D. Parra, E. Goyenechea, and J. A. Martinez, "Sirtuin gene expression in human mononuclear cells is modulated by caloric restriction, " European Journal of Clinical Investigation, vol. 38, no. 9, pp. 672-678, 2008.
77. Y.-T. Huang, J. Z. J. Maccani, N. L. Hawley, R. R. Wing, K. T. Kelsey, and J. M. McCaffery, "Epigenetic patterns in successful weight loss maintainers: a pilot study, " International Journal of Obesity, vol. 39, pp. 865-868, 2015.
78. H. Rosas-Vargas, J. D. Martínez-Ezquerro, and T. Bienvenu, "Brain-derived neurotrophic factor, food intake regulation, and obesity, " Archives of Medical Research, vol. 42, no. 6, pp. 482-494, 2011.
79. L. A. Lange, C. J. Willer, and S. S. Rich, "Recent developments in genome and exome-wide analyses of plasma lipids, " Current Opinion in Lipidology, vol. 26, no. 2, pp. 96-102, 2015.
80. A. Parihar, G. C. Wood, X. Chu et al., "Extension of GWAS results for lipid-related phenotypes to extreme obesity using Electronic Health Record (EHR) data and the Metabochip, " Frontiers in Genetics, vol. 5, article 222, 2014.
81. G. Xu, L.-X. Pan, H. Li et al., "Dietary cholesterol stimulates CYP7A1 in rats because farnesoid X receptor is not activated, " The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 286, no. 5, pp. G730-G735, 2004.
82. S. Lim and R. H. Eckel, "Pharmacological treatment and therapeutic perspectives of metabolic syndrome, " Reviews in Endocrine and Metabolic Disorders, vol. 15, no. 4, pp. 329-341, 2014.